Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04217057 · ClinicalTrials.gov registry record · Phase 1
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04217057 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT04217057, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
CCR2 is a significant prognostic biomarker in head and neck cancer. Currently there is no clinical biomarker to study CCR2, its prognostic significance or to select patients for CCR2-targeted therapy and to monitor response to such therapy. The investigators have developed a CCR2 specific PET radiotracer based on the peptide, ECL1i (d(LGTFLKC)) and radiolabeled with 64Cu (64Cu-DOTA-ECL1i). The investigators have found that 64Cu-DOTA-ELC1i specific binding has been demonstrated in human head and neck cancer tissue.
Interventions
- DRUG 64Cu-DOTA-ECL1i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-02-07 |
| Est. Completion | 2023-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04217057
The ClinicalTrials.gov registry entry for NCT04217057 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 64Cu-DOTA-ECL1i is the first listed.
NCT04217057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04217057 about?
NCT04217057 is a clinical study titled "Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer". CCR2 is a significant prognostic biomarker in head and neck cancer. Currently there is no clinical biomarker to study CCR2, its prognostic significance or to select patients for CCR2-targeted therapy and to monitor response to such therapy. The investigators have developed a CCR2 specific PET radiot...
What is the current status of trial NCT04217057?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-02-07. Estimated completion is 2023-02-07.
What interventions are being tested in trial NCT04217057?
The interventions under investigation include: 64Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT04217057?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.